Meeting date 23 February 2022
Recommendations on vaccination of children 5 - 11 years with mRNA vaccine from the Pfizer laboratory
Maintain homologous schedules using the vaccines authorized for the different age groups (Sinopharm 3 and 4 years, Pfizer 5 to 11 years).
Administer an additional dose in cases of immunocompromised hosts using the same vaccine as the one used previously.
Wait for further evidence before recommending a booster dose in the 3 to 11 years age group.
Work on the availability of vaccines at the jurisdictional level.
Increase efforts to reach the unvaccinated population.
Co-administration with other vaccines is recommended.
Implement strategies for the recovery of coverage for routine vaccines schedule vaccines.
Mots-clés